Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients With Metastatic Prostate Cancer

Journal article

Publication Details

Author(s): Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P
Journal: Clinical Nuclear Medicine
Publication year: 2018
Volume: 43
Journal issue: 8
Pages range: e250-e258
ISSN: 0363-9762


BACKGROUND: We investigated the role of Tc-MIP-1404 (Progenics Pharmaceuticals, Inc, New York, NY) SPECT/CT of PSMA expression in the assessment of treatment response in patients with metastatic prostate cancer.
METHODS: We retrospectively analyzed Tc-MIP-1404 SPECT/CT scans from 28 patients with metastatic prostate cancer examined before initiation and after completion of therapy. Eight of these patients had been treated with androgen deprivation therapy, 10 with docetaxel, and another 10 with external beam radiotherapy. On the CT images from SPECT/CT, treatment response was assessed according to RECIST 1.1 criteria; independently from that analysis, maximal standardized uptake values (SUVmax) were quantified in representative tumor lesions and treatment response assumed at differences in SUVmax greater than 30%. Radiographic response assessment was correlated to biochemical response (BR) based on prostate-specific antigen serum levels.
RESULTS: The concordance rate between SPECT and BR was 75% (95% confidence interval [CI], 0.55-0.89) (Cohen κ = 0.57; 95% CI, 0.29-0.85; P ≤ 0.01), higher than for that between SPECT and CT with 57% (95% CI, 0.37-0.76) (κ = 0.40; 95% CI, 0.14-0.65; P ≤ 0.01), as well as that between CT and BR with 50% (95% CI, 0.31-0.69) (κ = 0.31; 95% CI, 0.06-0.57, P ≤ 0.05). Discordant findings between SPECT and CT were most likely due to limitations of CT in assessing metastases in lymph nodes, as well as bone involvement, which was sometimes not detectable on CT scans.
CONCLUSIONS: The high agreement between treatment response, as assessed by Tc-MIP-1404 SPECT/CT and BR, suggests a possible role of that imaging tool for monitoring treatment in metastatic prostate cancer. Larger, ideally prospective trials are needed to help to reveal the full potential of SPECT imaging of PSMA expression in that regard.

FAU Authors / FAU Editors

Bäuerle, Tobias Prof. Dr.
Professur für Multimodale Bildgebung in der präklinischen Forschung
Beck, Michael
Lehrstuhl für Klinische Nuklearmedizin
Cordes, Michael Prof. Dr.
Medizinische Fakultät
Goebell, Peter Prof. Dr.
Urologische Klinik
Kuwert, Torsten Prof. Dr.
Lehrstuhl für Klinische Nuklearmedizin
Prante, Olaf Prof. Dr.
Professur für Molekulare Bildgebung und Radiochemie
Ritt, Philipp Dr.-Ing.
Nuklearmedizinische Klinik
Schmidkonz, Christian Dr.
Medizinische Fakultät
Schmidt, Daniela PD Dr.
Medizinische Fakultät
Uder, Michael Prof. Dr.
Lehrstuhl für Diagnostische Radiologie
Wullich, Bernd Prof. Dr.
Lehrstuhl für Urologie

How to cite

Schmidkonz, C., Cordes, M., Beck, M., Goetz, T.I., Schmidt, D., Prante, O.,... Ritt, P. (2018). Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients With Metastatic Prostate Cancer. Clinical Nuclear Medicine, 43(8), e250-e258.

Schmidkonz, Christian, et al. "Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients With Metastatic Prostate Cancer." Clinical Nuclear Medicine 43.8 (2018): e250-e258.


Last updated on 2019-26-02 at 18:10